News list for "Meglutide"

Weight-loss version of smegerutide Chinese manual updated to include cardiovascular benefit results

On April 21, the reporter learned from Novo Nordisk that the National Drug Administration of China (NMPA) approved the update of the instructions of Novo (weight-reduced version of smegerutide 2.4mg). This update is based on the main results of SELECT (Smegerutide Cardiovascular Outcomes Trial in Overweight or Obese Patients): In overweight or obese adult patients with diagnosed cardiovascular disease without diabetes, Novo reduced the risk of major adverse cardiovascular events (MACE, including...

clock
2025-04-21 07:52:10
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.